Abstract:γ-aminobutyric acid type A receptors (GABAARs) are the major mediators of synaptic inhibition in the brain. Aberrant GABAAR activity or regulation is observed in various neurodevelopmental disorders, neurodegenerative diseases and mental illnesses, including epilepsy, Alzheimer's and schizophrenia. Benzodiazepines, anesthetics and other pharmaceutics targeting these receptors find broad clinical use, but their inherent lack of receptor subtype specificity causes unavoidable side effects, raising a need for new or adjuvant medications. In this review article, we introduce a new strategy to modulate GABAeric signaling: targeting the intracellular protein interactors of GABAARs. Of special interest are scaffolding, anchoring and supporting proteins that display high GABAAR subtype specificity. Recent efforts to target gephyrin, the major intracellular integrator of GABAergic signaling, confirm that GABAAR-associated proteins can be successfully targeted through diverse molecules, including recombinant proteins, intrabodies, peptide-based probes and small molecules. Small-molecule artemisinins and peptides derived from endogenous interactors, that specifically target the universal receptor binding site of gephyrin, acutely affect synaptic GABAAR numbers and clustering, modifying neuronal transmission. Interference with GABAAR trafficking provides another way to modulate inhibitory signaling. Peptides blocking the binding site of GABAAR to AP2 increase the surface concentration of GABAAR clusters and enhance GABAergic signaling. Engineering of gephyrin binding peptides delivered superior means to interrogate neuronal structure and function. Fluorescent peptides, designed from gephyrin binders, enable live neuronal staining and visualization of gephyrin in the post synaptic sites with submicron resolution. We anticipate that in the future, novel fluorescent probes, with improved size and binding efficiency, may find wide application in super resolution microscopy studies, enlightening the nanoscale architecture of the inhibitory synapse. Broader studies on GABAAR accessory proteins and the identification of the exact molecular binding interfaces and affinities will advance the development of novel GABAAR modulators and following in vivo studies will reveal their clinical potential as adjuvant or stand-alone drugs.

Neurexins and Neuroligins: New Partners for GABA A Receptors at Synapses

Gaba(A) Receptor Mutations Associated with Generalized Epilepsies

Neurexins Physically and Functionally Interact with GABAA Receptors

Pumping the Brakes: Suppression of Synapse Development by MDGA–neuroligin Interactions

A Negative Regulator of Synaptic Development: MDGA and Its Links to Neurodevelopmental Disorders

Translational Patterns of Ionotropic Glutamate and GABA Receptors During Brain Development and Behavioral Stimuli Revealed by Polysome Profiling

Neurexins regulate presynaptic GABAB-receptors at central synapses

Targeting GABAAR-Associated Proteins: New Modulators, Labels and Concepts

Evolution of Neurotransmitter Gamma-Aminobutyric Acid, Glutamate and Their Receptors

GABAA receptors and neuroligin 2 synergize to promote synaptic adhesion and inhibitory synaptogenesis

GABA(A) receptor diversity and pharmacology

{gamma}1 GABAA Receptors in Spinal Nociceptive Circuits

The Progress of GABAB Receptor Regulation Mechanism

Structure–Function Relationships of Glycine and GABAA Receptors and Their Interplay With the Scaffolding Protein Gephyrin

Neurexins control the strength and precise timing of glycinergic inhibition in the auditory brainstem

Significance of GABAA Receptors in the Development of Some Neuropsychiatric Diseases

Transportation and Role of GABAA Receptor in Neurological Diseases

Neurexins and Neuroligins: Recent Insights from Invertebrates

Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy

Interacting Partners of AMPA-type Glutamate Receptors.